Table II.

Clinical efficacy (continuous endpoints) of fixed-dose combinations (FDC) compared with free-equivalent combinations (FECs): persistence defined as average duration of treatment

Study	FDC group Mean ± SD (N)	FEC group Mean ± SD (N)	Effect size (95% CI)	P-value
Zeng et al. 2010 [35]	215.56 ± NA (2213)	174.48 ± NA (2312)	HR = 0.66 (0.63–0.70)	< 0.001
Ferrario et al. 2013 [36]	339.76 ±224.08 (2146)	233.72 ±238.56 (1513)	MD = 106.04 (90.90–121.18)	< 0.001

HR – hazard ratio, MD – mean difference, NA – not available.